62307 Improvements in Sleep and Pruritus With Abrocitinib Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE DARE Study

Le résumé fourni par la source

Introduction Patients with atopic dermatitis (AD) may experience intense pruritus and sleep loss, constituting a substantial burden on quality of life. The objectives of this study were to assess the efficacy of abrocitinib versus dupilumab on sleep outcomes and pruritus in patients with moderate-to-severe AD. Procedure/Study This post hoc analysis included data from adults (≥18 years) with moderate-to-severe AD who received oral abrocitinib (200 mg once daily) or subcutaneous dupilumab (300 mg once every 2 weeks following a 600-mg loading dose) with concomitant topical therapy in phase 3 JADE DARE (NCT04345367; 26 weeks). Assessments were least squares mean (LSM) change from baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) quantity of hours slept and sleep disturbance scores and SCORing Atopic Dermatitis (SCORAD) total score and visual analog scale (SCORAD-VAS) pruritus and sleep loss scores. Results Data were included from 362 and 365 patients treated with abrocitinib and dupilumab, respectively. At Week 12, LSM change from baseline was greater with abrocitinib versus dupilumab for MOS-SS quantity of hours slept (0.7 [95% CI, 0.5, 0.9] vs 0.5 [0.2, 0.7]) and sleep disturbance (−20.5 [−22.3, −18.8] vs −16.4 [−18.1, −14.7]) scores. LSM change from baseline was greater for abrocitinib than dupilumab at Week 2 for SCORAD total score (−44.5 [95% CI, −47.0, −42.1] vs −33.5 [−35.9, −31.0]) and SCORAD-VAS sleep loss (−3.7 [−3.9, −3.4] vs −2.6 [−2.8, −2.3]) and pruritus (−4.2 [−4.4, −3.9] vs −2.8 [−3.0, −2.6]) scores. At Week 26, improvements across assessments were numerically greater with abrocitinib versus dupilumab. Conclusion Patients experienced more rapid improvements in sleep and pruritus outcomes with abrocitinib 200 mg versus dupilumab, and improvements were consistently numerically greater with abrocitinib. Funding/Disclosures This study was funded by Pfizer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.